Introduction
Pemrest 100 mg (Pembrolizumab) is a groundbreaking, highly advanced oncology medication classified as a humanized monoclonal antibody and immune checkpoint inhibitor. Manufactured under strict quality controls by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, Pemrest represents a paradigm shift in precision cancer care. Rather than directly targeting tumor cells, this immunotherapy unmasks the patient’s own immune system, enabling T-cells to recognize, target, and destroy malignant cells across a vast array of aggressive, advanced, and metastatic cancers.
Indications
Pemrest 100 mg (Pembrolizumab) is indicated for the treatment of multiple adult and pediatric cancer types, including:
- Metastatic Melanoma: Unresectable or metastatic melanoma.
- Non-Small Cell Lung Cancer (NSCLC): First-line or subsequent treatment for metastatic NSCLC whose tumors express PD-L1, or in combination with chemotherapy.
- Head and Neck Squamous Cell Carcinoma (HNSCC): Metastatic or unresectable recurrent HNSCC.
- Classical Hodgkin Lymphoma (cHL): Relapsed or refractory cHL.
- Urothelial Carcinoma: Advanced or metastatic bladder and urinary tract cancer.
- MSI-H or dMMR Solid Tumors: Unresectable or metastatic solid tumors that exhibit Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) biomarkers following prior systemic therapies.
- Triple-Negative Breast Cancer (TNBC): High-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, or locally recurrent/metastatic TNBC expressing PD-L1.
- Renal Cell Carcinoma (RCC): Advanced RCC in combination with tyrosine kinase inhibitors (TKIs) like axitinib or lenvatinib.
Pharmacology
Pembrolizumab, the active agent in Pemrest 100 mg, is a humanized monoclonal IgG4 kappa antibody.
- Mechanism of Action: Many cancer cells exploit the programmed death-1 (PD-1) pathway to hide from the immune system by binding to receptors on T-cells, effectively switching off the body’s anti-tumor response.
- Immune Reactivation: Pembrolizumab selectively binds to the PD-1 receptor on T-lymphocytes, blocking its interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This competitive inhibition prevents the down-regulation of T-cells, re-activating the native cellular immune system to identify and systematically clear tumor cells.
Dosage & Administration
Intravenous (IV) Infusion for Adults:
- Standard Fixed Dosing: The recommended dose is 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion.
- Infusion Duration: Must be administered intravenously over 30 minutes through an explicit dedicated line.
- Reconstitution & Dilution:
- Withdraw the required volume of Pemrest (each 4 mL vial contains 100 mg of pembrolizumab, yielding a concentration of 25 mg/mL).
- Dilute into an IV bag containing either 0.9% Sodium Chloride Mgection or 5% Dextrose Mgection to achieve a final concentration between 1 mg/mL and 10 mg/mL. Mix by gentle inversion; do not shake.
- Note: Must be prepared and administered exclusively by experienced oncology nurses and clinicians. Never administer as an intravenous push or bolus.
Drug Interactions
- Systemic Corticosteroids: Avoid the use of high-dose systemic corticosteroids or immunosuppressants before starting Pemrest, as they may interfere with the immune-activating mechanism of action. However, systemic corticosteroids can and should be used after initiating therapy to manage immune-mediated adverse reactions.
- Drug Clearance: Monoclonal antibodies are cleared via standard protein catabolism pathways; therefore, classic cytochrome P450 (CYP) drug-metabolic interactions do not occur.
Contraindications
- Hypersensitivity: Severe, life-threatening hypersensitivity or anaphylaxis to Pembrolizumab or any of the structural excipients in the vial formulation.
Side Effects
Pemrest works by activating the immune system, which can cause the body to attack healthy organs. Side effects are primarily immune-mediated adverse reactions (imARs):
- Dermatological: Pruritus (itching), skin rash, vitiligo, and dry skin.
- Gastrointestinal: Immune-mediated colitis, severe diarrhea, nausea, and abdominal pain.
- Endocrine System: Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, and Type 1 Diabetes Mellitus.
- Respiratory: Immune-mediated pneumonitis (characterized by shortness of breath, hypoxia, or cough).
- Systemic: Fatigue, musculoskeletal pain, decreased appetite, and pyrexia (fever).
Pregnancy & Lactation
- Pregnancy: Based on its mechanism, Pemrest can cause fetal harm or loss when administered to a pregnant woman. Females of reproductive potential must verify a negative pregnancy status before initiation and utilize effective contraception during treatment and for at least 4 months after the final dose.
- Lactation: Because maternal antibodies can pass into human milk, breast-feeding is strictly discouraged during treatment and for 4 months following the final dose.
Precautions & Warnings
- Severe Pneumonitis: Monitor patients closely for radiographic changes or new pulmonary symptoms. Withhold Pemrest for moderate pneumonitis; permanently discontinue for severe or life-threatening pneumonitis and initiate systemic corticosteroids ($1 \text{ to } 2 \text{ mg/kg/day}$ prednisone equivalent).
- Immune-Mediated Colitis: Evaluate patients presenting with severe diarrhea. Treat with high-dose corticosteroids based on severity and temporarily withhold or permanently discontinue Pemrest.
- Hepatotoxicity & Nephritis: Monitor liver enzymes (ALT/AST, bilirubin) and renal function (creatinine) before each infusion cycle.
- Infusion-Related Reactions: Monitor patients during the infusion for signs of anaphylaxis, rigors, chills, or hypotension. Discontinue immediately if severe infusion reactions occur.
Use in Special Populations
- Pediatric Use: Safety and effectiveness have been established in pediatric patients with relapsed/refractory cHL, advanced MSI-H tumors, or high-risk melanoma at adjusted mg/kg doses.
- Hepatic/Renal Impairment: No dose adjustments are required for patients with mild-to-moderate liver or kidney impairment.
Overdose Effects
There is no specific antidote for an overdose of Pembrolizumab. In the event of an accidental overdose, patients must be strictly monitored for exaggerated immune-mediated adverse reactions and handled with immediate supportive and corticosteroid-driven anti-inflammatory therapies.
Storage & Stability
- Intact Vials: Store under refrigeration between 2°C to 8°C (36°F to 46°F) inside the original carton to protect from direct light. Do not freeze and do not shake.
- Diluted Solution: The diluted IV infusion solution is stable at room temperature for up to 6 hours (including infusion time) or under refrigeration ($2^\circ\text{C to } 8^\circ\text{C}$) for up to 96 hours. If refrigerated, allow the IV bag to reach room temperature before administration.
Supplier Information
Onco Solution is an established premier global oncology medicine supplier dedicated to bridging crucial gaps in advanced international cancer care. We guarantee the secure, stringently temperature-controlled (cold chain, 2°C–8°C) and authentic distribution of breakthrough immunotherapies like Pemrest 100 mg. For global clinical quotes, validation paperwork, or wholesale export inquiries, visit www.oncosolution.com.
Manufacturer Information
Pemrest 100 mg is manufactured under international cGMP standards by Everest Pharmaceuticals Ltd., a premier high-tech pharmaceutical manufacturer in Bangladesh recognized globally for producing world-class generic oncology, biotech, and targeted life-saving pipelines.
